Cargando…
PRMDA: personalized recommendation-based MiRNA-disease association prediction
Recently, researchers have been increasingly focusing on microRNAs (miRNAs) with accumulating evidence indicating that miRNAs serve as a vital role in various biological processes and dysfunctions of miRNAs are closely related with human complex diseases. Predicting potential associations between mi...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689632/ https://www.ncbi.nlm.nih.gov/pubmed/29156742 http://dx.doi.org/10.18632/oncotarget.20996 |
Sumario: | Recently, researchers have been increasingly focusing on microRNAs (miRNAs) with accumulating evidence indicating that miRNAs serve as a vital role in various biological processes and dysfunctions of miRNAs are closely related with human complex diseases. Predicting potential associations between miRNAs and diseases is attached considerable significance in the domains of biology, medicine, and bioinformatics. In this study, we developed a computational model of Personalized Recommendation-based MiRNA-Disease Association prediction (PRMDA) to predict potential related miRNA for all diseases by implementing personalized recommendation-based algorithm based on integrated similarity for diseases and miRNAs. PRMDA is a global method capable of prioritizing candidate miRNAs for all diseases simultaneously. Moreover, the model could be applied to diseases without any known associated miRNAs. PRMDA obtained AUC of 0.8315 based on leave-one-out cross validation, which demonstrated that PRMDA could be regarded as a reliable tool for miRNA-disease association prediction. Besides, we implemented PRMDA on the HMDD V1.0 and HMDD V2.0 databases for three kinds of case studies about five important human cancers in order to test the performance of the model from different perspectives. As a result, 92%, 94%, 88%, 96% and 88% out of the top 50 candidate miRNAs predicted by PRMDA for Colon Neoplasms, Esophageal Neoplasms, Lymphoma, Lung Neoplasms and Breast Neoplasms, respectively, were confirmed by experimental reports. |
---|